Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities

References

• Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369. doi: 10.1136/BMJ.M1590
   Google Scholar
• Armstrong AW, Bohannan B, Mburu S, et al. Patient perspectives on psoriatic disease burden: results from the global psoriasis and beyond survey. Dermatology. 2023;239(4):621. doi: 10.1159/000528945
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi: 10.1016/S0140-6736(14)61909-7
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. doi: 10.1056/NEJMRA0804595
   PubMed Web of Science ®Google Scholar
• Zeng C, Tsoi LC, Gudjonsson JE. Dysregulated epigenetic modifications in psoriasis. Exp Dermatol. 2021;30(8):1156–1166. doi: 10.1111/EXD.14332
   PubMed Web of Science ®Google Scholar
• Kamiya K, Kishimoto M, Sugai J, et al. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347. doi: 10.3390/IJMS20184347
   PubMed Web of Science ®Google Scholar
• Jin JQ, Elhage KG, Spencer RK, et al. Mendelian randomization studies in psoriasis and psoriatic arthritis: a systematic review. J Invest Dermatol. 2023;143(5):762–776.e3. doi: 10.1016/j.jid.2022.11.014
   PubMed Web of Science ®Google Scholar
• Patrick MT, Li Q, Wasikowski R, et al. Shared genetic risk factors and causal association between psoriasis and coronary artery disease. Nat Commun. 2022;13(1). doi: 10.1038/S41467-022-34323-4
   Web of Science ®Google Scholar
• V CC, Meena D, Manou M, et al. Multiple long-term conditions in people with psoriasis: a latent class and bidirectional Mendelian randomization analysis. Br J Dermatol. Published online Oct 24, 2023;190(3):364–373. doi: 10.1093/BJD/LJAD410
   PubMedGoogle Scholar
• Girolomoni G, Savage L, Gisondi P, et al. Increasing access to effective systemic treatments in patients with moderate-to-severe psoriasis: narrative review. Dermatol Ther (Heidelb). Cites Sep 14, 2023;13(10):2171–2185. doi: 10.1007/S13555-023-01014-X
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Carrascosa, JM, Puig L, et al. Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the treatment of psoriasis with biologic therapy. Actas Dermosifiliogr. 2022;113(3):261–277.
   PubMed Web of Science ®Google Scholar
• Carrascosa JM, Puig L, Romero IB, et al. Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the treatment of psoriasis with biologic agents: Part 2 - management of special populations, patients with comorbid conditions, and risk. Actas Dermosifiliogr. 2022;113(6):583–609. doi: 10.1016/j.ad.2022.01.024
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461–2498. doi: 10.1111/JDV.16915
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317. doi: 10.1111/JDV.16926
   PubMed Web of Science ®Google Scholar
• Camiña-Conforto G, Mateu-Arrom L, López-Ferrer A, et al. Bimekizumab in the treatment of plaque psoriasis: focus on patient selection and perspectives. Patient Prefer Adherence. 2023;17:1541–1549. doi: 10.2147/PPA.S350760
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535. doi: 10.1002/14651858.CD011535.pub5
   PubMedGoogle Scholar
• Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214(2):149–160. doi: 10.1002/PATH.2287
   PubMed Web of Science ®Google Scholar
• Chokshi A, Demory Beckler M, Laloo A, et al. Paradoxical tumor necrosis factor-alpha (TNF-α) inhibitor-induced psoriasis: a systematic review of pathogenesis, clinical presentation, and treatment. Cureus. 2023;15(8). doi: 10.7759/CUREUS.42791
   Web of Science ®Google Scholar
• Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):1–16. doi: 10.3390/IJMS22052719
   Web of Science ®Google Scholar
• Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol. 2015;15(6):362–374. doi: 10.1038/NRI3834
   PubMed Web of Science ®Google Scholar
• Ogawa E, Sato Y, Minagawa A, et al. Pathogenesis of psoriasis and development of treatment. J Dermatol. 2018;45(3):264–272. doi: 10.1111/1346-8138.14139
   PubMed Web of Science ®Google Scholar
• Branisteanu D, Cojocaru C, Diaconu R, et al. Update on the etiopathogenesis of psoriasis (Review). Exp Ther Med. 2022;23(3). doi: 10.3892/ETM.2022.11124
   Web of Science ®Google Scholar
• Akhter S, Tasnin FM, Islam MN, et al. Role of Th17 and IL-17 cytokines on inflammatory and auto-immune diseases. Curr Pharm Des. 2023;29(26):2078–2090. doi: 10.2174/1381612829666230904150808
   PubMed Web of Science ®Google Scholar
• Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14(2):155–174. doi: 10.1016/S1359-6101(03)00002-9
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Nakae S, Saijo S, et al. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev. 2008;226(1):57–79. doi: 10.1111/J.1600-065X.2008.00699.X
   PubMed Web of Science ®Google Scholar
• Johnston A, Guzman AM, Swindell WR, et al. Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling. Br J Dermatol. 2014;171(1):97–107. doi: 10.1111/BJD.12937
   PubMed Web of Science ®Google Scholar
• Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64:66–73. doi: 10.1016/J.JAUT.2015.07.008
   PubMed Web of Science ®Google Scholar
• Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet. 2007;80(2):273–290. doi: 10.1086/511051
   PubMed Web of Science ®Google Scholar
• Cingoz OU. Ustekinumab. MAbs. 2009;1(3):216–221. doi: 10.4161/MABS.1.3.8593
   PubMed Web of Science ®Google Scholar
• Hassett B, Singh E, Mahgoub E, et al. Manufacturing history of etanercept (Enbrel®): Consistency of product quality through major process revisions. MAbs. 2018;10(1):159–165. doi: 10.1080/19420862.2017.1388483
   PubMed Web of Science ®Google Scholar
• Ahmed SS, De A, Das S, et al. Biologics and biosimilars in psoriasis. Indian J Dermatol. 2023;68(3):282–295. doi: 10.4103/IJD.IJD_421_23
   PubMed Web of Science ®Google Scholar
• Van De Kerkhof PCM, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J Dermatol. 2008;159(5):1177–1185. doi: 10.1111/J.1365-2133.2008.08771.X
   PubMed Web of Science ®Google Scholar
• Dodero-Anillo JM, Lozano-Cuadra IC, Rios-Sanchez E, et al. Optimising the therapeutic interval for biologics in patients with psoriasis. Life (Basel). 2022;12(12):2075. doi: 10.3390/LIFE12122075
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366(9494):1367–1374. doi: 10.1016/S0140-6736(05)67566-6
   PubMed Web of Science ®Google Scholar
• Shear NH, Hartmann M, Toledo-Bahena M, et al. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice. Br J Dermatol. 2014;171(3):631–641. doi: 10.1111/BJD.13004
   PubMed Web of Science ®Google Scholar
• Li C, Sunhe Y, Zhou H, et al. Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis. J DermatolTreat. 2023;34(1). doi: 10.1080/09546634.2023.2249145
   Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–566. doi: 10.1111/J.1365-2133.2007.08315.X
   PubMed Web of Science ®Google Scholar
• Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from reveal. J Am Acad Dermatol. 2012;66(2):241–251. doi: 10.1016/J.JAAD.2010.12.005
   PubMed Web of Science ®Google Scholar
• Menting SP, Van Lümig PPM, De Vries ACQ, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol. 2014;150(2):130–136. doi: 10.1001/JAMADERMATOL.2013.8347
   PubMed Web of Science ®Google Scholar
• Gisondi P, Gottlieb AB, Elewski B, et al. Long-term health-related quality of life in patients with plaque psoriasis treated with certolizumab pegol: three-year results from two randomised phase 3 studies (CIMPASI-1 and CIMPASI-2). Dermatol Ther (Heidelb). 2023;13(1):315–328. doi: 10.1007/S13555-022-00861-4
   PubMed Web of Science ®Google Scholar
• Warren RB, Lebwohl M, Sofen H, et al. Three‐year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. J Eur Acad Dermatol Venereol. 2021;35(12):2398. doi: 10.1111/JDV.17486
   PubMed Web of Science ®Google Scholar
• Ryan C, Sobell JM, Leonardi CL, et al. Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis. Am J Clin Dermatol. 2018;19(3):437–447. doi: 10.1007/S40257-017-0341-6
   PubMed Web of Science ®Google Scholar
• Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018;24 Suppl 2:S10–S20. doi: 10.1016/J.CMI.2017.12.025
   PubMed Web of Science ®Google Scholar
• Roach DR, Bean AGD, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol. 2002;168(9):4620–4627. doi: 10.4049/JIMMUNOL.168.9.4620
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz M. Assessment of latent infections in patients receiving biological therapies. Rev Esp Quimioter. 2019 Cites 2023 Nov 6;32(Suppl 2):63. doi: 10.1016/j.cmi.2018.01.029 /pmc/articles/PMC6755370/.
   PubMedGoogle Scholar
• Lambert JLW, Segaert S, Ghislain PD, et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2). J Eur Acad Dermatol Venereol. 2020;34(9):1914–1923. doi: 10.1111/JDV.16683
   PubMed Web of Science ®Google Scholar
• Piaserico S, Messina F, Russo FP. Managing psoriasis in patients with HBV or HCV infection: practical considerations. Am J Clin Dermatol. 2019;20(6):829–845. doi: 10.1007/S40257-019-00457-3
   PubMed Web of Science ®Google Scholar
• Silfvast-Kaiser AS, Homan KB, Mansouri B. A narrative review of psoriasis and multiple sclerosis: links and risks. Psoriasis (Auckl). 2019;9:81–90. doi: 10.2147/PTT.S186637
   PubMed Web of Science ®Google Scholar
• Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep. 2017;17(4). doi: 10.1007/S11910-017-0742-1
   PubMed Web of Science ®Google Scholar
• Gregory AP, Dendrou CA, Attfield KE, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 2012;488(7412):508–511. doi: 10.1038/NATURE11307
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–3140. doi: 10.1161/01.CIR.0000077913.60364.D2
   PubMed Web of Science ®Google Scholar
• Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA. 2005;102(9):3372–3377. doi: 10.1073/PNAS.0408506102
   PubMed Web of Science ®Google Scholar
• Müller S, Welchowski T, Schmid M, et al. Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the “Flip-Flop” phenomenon). Allergy. 2024;79(1):164–173. doi: 10.1111/ALL.15921 Published online 2023.
   PubMedGoogle Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674. doi: 10.1016/S0140-6736(08)60725-4
   PubMed Web of Science ®Google Scholar
• Gönülal M, Balcı DD, Öztürk A, et al. Effectiveness and safety of ustekinumab for the treatment of psoriasis; six years of clinical experience. J DermatolTreat. 2023;34(1). doi: 10.1080/09546634.2023.2241941
   Google Scholar
• Reich K, Warren RB, Coates LC, et al. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. J Eur Acad Dermatol Venereol. 2020;34(6):1161–1173. doi: 10.1111/JDV.16124
   PubMed Web of Science ®Google Scholar
• Augustin M, Sator PG, von Kiedrowski R, et al. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study. J Eur Acad Dermatol Venereol. 2022;36(10):1796–1804. doi: 10.1111/JDV.18329
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Lacour JP, Korman N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. J Eur Acad Dermatol Venereol. 2017;31(4):679–685. doi: 10.1111/JDV.13990
   PubMed Web of Science ®Google Scholar
• Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553–559. doi: 10.1111/JDV.15288
   PubMed Web of Science ®Google Scholar
• Carmona-Rocha E, Puig L. Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium. Immunotherapy. 2023;15(15):1209–1225. doi: 10.2217/IMT-2023-0013
   PubMed Web of Science ®Google Scholar
• Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today (Barc). 2017;53(5):283–297. doi: 10.1358/DOT.2017.53.5.2613690
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286. doi: 10.1111/BJD.14493
   PubMed Web of Science ®Google Scholar
• Reich K, Iversen L, Puig L, et al. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3. J Eur Acad Dermatol Venereol. 2022;36(8):1275–1283. doi: 10.1111/JDV.18068
   PubMed Web of Science ®Google Scholar
• Armstrong A, Fahrbach K, Leonardi C, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(8):1777–1792. doi: 10.1007/S13555-022-00760-8
   PubMed Web of Science ®Google Scholar
• Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–486. doi: 10.1016/S0140-6736(21)00126-4
   PubMed Web of Science ®Google Scholar
• Thaçi D, Vender R, De Rie MA, et al. Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. Br J Dermatol. 2023;188(1):22–31. doi: 10.1093/BJD/LJAC021
   PubMed Web of Science ®Google Scholar
• Edupuganti S, Khine S, Gupta R, et al. Secukinumab-induced crohn’s disease in a patient treated for juvenile idiopathic arthritis. Cureus. 2023;15(8). doi: 10.7759/CUREUS.43825
   Web of Science ®Google Scholar
• Esplugues E, Huber S, Gagliani N, et al. Control of TH17 cells occurs in the small intestine. Nature. 2011;475(7357):514–518. doi: 10.1038/NATURE10228
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2016;111(11):1599–1607. doi: 10.1038/AJG.2016.298
   PubMed Web of Science ®Google Scholar
• Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332(6025):65–68. doi: 10.1126/SCIENCE.1200439
   PubMed Web of Science ®Google Scholar
• Roman M, Chiu MW. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;11:2065. doi: 10.2147/DDDT.S113683
   PubMed Web of Science ®Google Scholar
• Daniele SG, Eldirany SA, Ho M, et al. Structural basis for differential p19 targeting by IL-23 biologics. bioRxiv. 1–18. DOI: 10.1101/2023.03.09.531913 Published online 2023.
   Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. doi: 10.1016/J.JAAD.2016.11.041
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled voyage 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. doi: 10.1016/J.JAAD.2016.11.042
   PubMed Web of Science ®Google Scholar
• Nakamura M, Lee K, Jeon C, et al. Guselkumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther (Heidelb). 2017;7(3):281–292. doi: 10.1007/S13555-017-0187-0
   PubMed Web of Science ®Google Scholar
• Papp KA, Blauvelt A, Puig L, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the limmitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol. 2023;89(3):AB62. doi: 10.1016/J.JAAD.2023.07.1024 Published online 2023.
   Web of Science ®Google Scholar
• Costanzo A, Llamas-Velasco M, Fabbrocini G, et al. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. J Eur Acad Dermatol Venereol. 2023;37(10):2004–2015. doi: 10.1111/JDV.19229
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Soliman AM, Betts KA, et al. Long-term benefit-risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(1):167–184. doi: 10.1007/S13555-021-00647-0
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A, Ehst BD, et al. Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review. Adv Ther. 2023;40(8):3410–3433. doi: 10.1007/S12325-023-02568-0
   PubMed Web of Science ®Google Scholar
• Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525–534. doi: 10.1080/1744666X.2017.1292137
   PubMed Web of Science ®Google Scholar
• Rusiñol L, Carmona-Rocha E, Puig L. Durability and long-term outcomes of biologic therapies in psoriasis. Expert Rev Clin Immunol. 2024;20(1):71–82. doi: 10.1080/1744666X.2023.2250918 Published online 2023.
   PubMed Web of Science ®Google Scholar
• Dauden E, Blasco AJ, Bonanad C, et al. Position statement for the management of comorbidities in psoriasis. J Eur Acad Dermatol Venereol. 2018;32(12):2058–2073. doi: 10.1111/JDV.15177
   PubMed Web of Science ®Google Scholar
• Gerdes S, Zahl VA, Knopf H, et al. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol. 2008;159(5):1116–1123. doi: 10.1111/J.1365-2133.2008.08786.X
   PubMed Web of Science ®Google Scholar
• Kimball AB, Bensimon AG, Guerin A, et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol. 2011;12(1):51–62. doi: 10.2165/11530640-000000000-00000
   PubMed Web of Science ®Google Scholar
• Ko SH, Chi CC, Yeh ML, et al. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019;2019(7). doi: 10.1002/14651858.CD011972.PUB2
   Google Scholar
• Barros G, Duran P, Vera I, et al. Exploring the links between obesity and psoriasis: a comprehensive review. Int J Mol Sci. 2022;23(14):7499. doi: 10.3390/IJMS23147499
   PubMed Web of Science ®Google Scholar
• Constantin C, Surcel M, Munteanu A, et al. Insights into Nutritional Strategies in Psoriasis. Nutrients. 2023;15(16):3528. doi: 10.3390/NU15163528/S1
   PubMedGoogle Scholar
• Budu-Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: a Mendelian randomization study. PLoS Med. 2019;16(1):e1002739. doi: 10.1371/JOURNAL.PMED.1002739
   PubMed Web of Science ®Google Scholar
• Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007–1011. doi: 10.1111/J.1468-3083.2011.04065.X
   PubMed Web of Science ®Google Scholar
• Shao J, Xu Z, Xu Y. Integrated population pharmacokinetic analysis of ustekinumab across multiple Immune-Mediated Inflammatory disease Populations and healthy subjects. Eur J Drug Metab Pharmacokinet. 2022;47(4):537–548. doi: 10.1007/S13318-022-00768-7
   PubMed Web of Science ®Google Scholar
• Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162–175. doi: 10.1177/0091270008329556
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Foley P, et al. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III voyage 1 and voyage 2 studies. Br J Dermatol. 2018;178(1):132–139. doi: 10.1111/BJD.16008
   PubMed Web of Science ®Google Scholar
• Reich K, Puig L, Mallbris L, et al. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(7):1196–1207. doi: 10.1111/JDV.14252
   PubMed Web of Science ®Google Scholar
• Anghel F, Nitusca D, Cristodor P. Body mass index influence for the personalization of the monoclonal antibodies therapy for psoriasis. Life (Basel). 2021;11(12):1316. doi: 10.3390/LIFE11121316
   PubMed Web of Science ®Google Scholar
• Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLOS ONE. 2018;13(5):e0195123. doi: 10.1371/JOURNAL.PONE.0195123
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Soliman AM, Betts KA, et al. Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2021;11(3):885–905. doi: 10.1007/S13555-021-00511-1
   PubMed Web of Science ®Google Scholar
• Del Alcázar E, Ferran M, López-Ferrer A, et al. Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study. J DermatolTreat. 2020;31(3):222–226. doi: 10.1080/09546634.2019.1597245
   Google Scholar
• Zozaya N, Abdalla F, Alfonso Zamora S, et al. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Rev Pharmacoecon Outcomes Res. 2022;22(6):941–953. doi: 10.1080/14737167.2022.2063842
   PubMed Web of Science ®Google Scholar
• Dalamaga M, Papadavid E. Can we better strategize our choice of pharmacotherapy for patients with co-morbid psoriasis and obesity? Expert Opin Pharmacother. 2019;20(11):1303–1308. doi: 10.1080/14656566.2019.1603294
   PubMed Web of Science ®Google Scholar
• Pinter A, Gerdes S, Papavassilis C, et al. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis. J DermatolTreat. 2020;31(8):769–775. doi: 10.1080/09546634.2019.1626973
   Google Scholar
• Yao Z, Hu C, Zhu Y, et al. Population pharmacokinetic modeling of guselkumab, a Human IgG1λ Monoclonal Antibody Targeting IL-23, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2018;58(5):613–627. doi: 10.1002/JCPH.1063
   PubMed Web of Science ®Google Scholar
• Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6 months: a prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022;86(1):68–76. doi: 10.1016/J.JAAD.2021.06.883
   PubMed Web of Science ®Google Scholar
• Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525–2531. doi: 10.1001/JAMA.2011.878
   PubMed Web of Science ®Google Scholar
• Pina T, Armesto S, Lopez-Mejias R, et al. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study. J Eur Acad Dermatol Venereol. 2015;29(7):1325–1330. doi: 10.1111/JDV.12814
   PubMed Web of Science ®Google Scholar
• Stanley TL, Zanni MV, Johnsen S, et al. TNF-α antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab. 2011;96(1):E146–E150. doi: 10.1210/JC.2010-1170
   PubMed Web of Science ®Google Scholar
• Kofoed K, Clemmensen A, Mikkelsen UR, et al. Effects of anti-tumor necrosis factor therapy on body composition and insulin sensitivity in patients with psoriasis. Arch dermatol. 2012;148(9):1089–1091. doi: 10.1001/ARCHDERMATOL.2012.1753
   PubMedGoogle Scholar
• Martínez-Abundis E, Reynoso-Von Drateln C, Hernández-Salazar E, et al. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res. 2007;299(9):461–465. doi: 10.1007/s00403-007-0784-3
   PubMed Web of Science ®Google Scholar
• Lestre S, Diamantino F, Veloso L, et al. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol. 2011;21(6):916–920. doi: 10.1684/EJD.2011.1548
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. Effects of biologic therapy on laboratory indicators of cardiometabolic diseases in patients with psoriasis. J Clin Med. 2023;12(5):1934. doi: 10.3390/JCM12051934
   PubMed Web of Science ®Google Scholar
• Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–285. doi: 10.1111/J.1365-2036.2011.04724.X
   PubMed Web of Science ®Google Scholar
• Perez-Carreras M, Casis-Herce B, Rivera R, et al. Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: inflammatory cross-talk that needs a multidisciplinary approach. World J Gastroenterol. 2021;27(41):7113–7124. doi: 10.3748/WJG.V27.I41.7113
   PubMed Web of Science ®Google Scholar
• Gau SY, Huang KH, Lee CH, et al. Bidirectional association between psoriasis and nonalcoholic fatty liver disease: real-world evidence from two longitudinal cohort studies. Front Immunol. 2022;13:13. doi: 10.3389/FIMMU.2022.840106
   Web of Science ®Google Scholar
• Takezaki D, Morizane S, Ikeda K, et al. Co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis associated with decreased adiponectin expression in a murine model. Front Immunol. 2023;14:14. doi: 10.3389/FIMMU.2023.1214623
   Web of Science ®Google Scholar
• Carrascosa JM, Vilarrasa E, Belinchón I, et al. Common approach to metabolic-associated fatty liver disease in patients with psoriasis: consensus-based recommendations from a multidisciplinary group of experts. Actas Dermosifiliogr. 2023;114(5):392–401. doi: 10.1016/J.AD.2023.01.004
   PubMed Web of Science ®Google Scholar
• Yang Y, Han CY, Guan QB, et al. Interleukin-17-mediated inflammation promotes nonalcoholic fatty liver disease in mice with regulation of M1-type macrophage polarization. Zhonghua Gan Zang Bing Za Zhi. 2018;26(12):916–921. doi: 10.3760/CMA.J.ISSN.1007-3418.2018.12.008
   PubMedGoogle Scholar
• Gomes AL, Teijeiro A, Burén S, et al. Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma. Cancer Cell. 2016;30(1):161–175. doi: 10.1016/J.CCELL.2016.05.020
   PubMed Web of Science ®Google Scholar
• Gerdes S, Pinter A, Papavassilis C, et al. Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. J Eur Acad Dermatol Venereol. 2020;34(3):533–541. doi: 10.1111/JDV.16004
   PubMed Web of Science ®Google Scholar
• de Aragón C A-J, Berna-Rico E, Ballester-Martinez MA, et al. Early Detection and Progression of Subclinical Atherosclerosis in Psoriasis (EDSAP): protocol for an observational, single-centre, prospective cohort study. BMJ Open. 2023;13(9):e072455. doi: 10.1136/BMJOPEN-2023-072455
   PubMed Web of Science ®Google Scholar
• Lerman JB, Joshi AA, Chaturvedi A, et al. Coronary plaque characterization in psoriasis reveals high risk features which improve following treatment in a prospective observational study. Circulation. 2017;136(3):263. doi: 10.1161/CIRCULATIONAHA.116.026859
   PubMed Web of Science ®Google Scholar
• González-Cantero A, Ortega-Quijano D, Álvarez-Díaz N, et al. Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and Meta-Analysis of Randomized Placebo-Controlled Trials. J Invest Dermatol. 2021;141(10):2402–2411. doi: 10.1016/J.JID.2021.03.024
   PubMed Web of Science ®Google Scholar
• Cai R, Jin Y, Chen B, et al. Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis: A systematic review and aggregate data meta-analysis of randomized controlled trials. Int J Rheum Dis. 2023;26(4):625–637. doi: 10.1111/1756-185X.14603
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Kerdel F, Naldi L, et al. Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis. J Drugs Dermatol. 2017;16(10):1002–1013.
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864–871. doi: 10.1001/JAMA.2011.1211
   PubMed Web of Science ®Google Scholar
• Mattay SS, Zamani M, Saturno D, et al. Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis. Clin Gastroenterol Hepatol. Published online Oct 2023. doi: 10.1016/J.CGH.2023.09.033
   Google Scholar
• Hugh J, Van Voorhees AS, Nijhawan RI, et al. From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol. 2014;70(1):168–177. doi: 10.1016/J.JAAD.2013.09.020
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Gottlieb AB, Langley RG, et al. Signal detection and methodological limitations in a real-world registry: learnings from the evaluation of long-term safety analyses in PSOLAR. Drug Saf. 2021;44(6):699–709. doi: 10.1007/S40264-021-01065-Z
   PubMed Web of Science ®Google Scholar
• Khalid U, Ahlehoff O, Gislason GH, et al. Psoriasis and risk of heart failure: a nationwide cohort study. Eur J Heart Fail. 2014;16(7):743–748. doi: 10.1002/EJHF.113
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103(8):1044–1047. doi: 10.1161/01.CIR.103.8.1044
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40. doi: 10.1016/J.JAAD.2018.06.057
   PubMed Web of Science ®Google Scholar
• Champs B, Degboé Y, Barnetche T, et al. Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trials. RMD Open. 2019;5(1):e000763. doi: 10.1136/RMDOPEN-2018-000763
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91(SUPPL. 91):47–55. doi: 10.3899/JRHEUM.140102
   PubMedGoogle Scholar
• Gordon KB, Lebwohl M, Papp KA, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186(3):466–475. doi: 10.1111/BJD.20818
   PubMed Web of Science ®Google Scholar
• Manzanares N, Vilarrasa E, López A, et al. No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients. J Eur Acad Dermatol Venereol. 2024;38(1). Published online 2023. doi: 10.1111/JDV.19406
   PubMedGoogle Scholar
• Torres T, Chiricozzi A, Puig L, et al. Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: A retrospective, multinational, multicentre study. Am J Clin Dermatol. Published online 2024. doi:10.1007/S40257-024-00845-4.
   Web of Science ®Google Scholar
• Thatiparthi A, Martin A, Liu J, et al. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021;22(4):425–442. doi: 10.1007/S40257-021-00603-W
   PubMed Web of Science ®Google Scholar
• Sanz-Bueno J, Vanaclocha F, García-Doval I, et al. Risk of reactivation of hepatitis B virus infection in psoriasis patients treated with biologics: a retrospective analysis of 20 cases from the biobadaderm database. Actas Dermosifiliogr. 2015;106(6):477–482. doi: 10.1016/J.AD.2015.01.010
   PubMedGoogle Scholar
• Li L, Jiang X, Fu L, et al. Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis. Clin Exp Med. 2023;23(3):701–715. doi: 10.1007/S10238-022-00827-Y
   PubMed Web of Science ®Google Scholar
• Pauly MP, Tucker LY, Szpakowski JL, et al. Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2018;16(12):1964–1973.e1. doi: 10.1016/J.CGH.2018.04.033
   PubMed Web of Science ®Google Scholar
• Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol. 2021;27(19):2312. doi: 10.3748/WJG.V27.I19.2312
   PubMed Web of Science ®Google Scholar
• Chiu HY, Hui RCY, Huang YH, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study. Acta Derm Venereol. 2018;98(9):829–834. doi: 10.2340/00015555-2989
   PubMed Web of Science ®Google Scholar
• Megna M, Patruno C, Bongiorno MR, et al. Hepatitis virus reactivation in patients with psoriasis treated with secukinumab in a real-world setting of hepatitis B or hepatitis C infection. Clin Drug Investig. 2022;42(6):525–531. doi: 10.1007/S40261-022-01163-5
   PubMed Web of Science ®Google Scholar
• Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126–1136. doi: 10.1016/S0140-6736(20)30263-4
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Pavia G, Valenti M, et al. Safety of biologic therapies in patients with moderate-to-severe plaque psoriasis and concomitant viral hepatitis: a monocentric retrospective study. Dermatol Ther (Heidelb). 2022;12(5):1263–1270. doi: 10.1007/S13555-022-00726-W
   PubMed Web of Science ®Google Scholar
• Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature. J Am Acad Dermatol. 2017;77(1):88–97.e5. doi: 10.1016/J.JAAD.2017.01.037
   PubMed Web of Science ®Google Scholar
• Zein NN, The Etanercept Study Group F. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42(3):315–322. doi: 10.1016/J.JHEP.2004.11.025
   PubMed Web of Science ®Google Scholar
• Papp KA, Beecker J, Cooper C, et al. Use of systemic therapies for treatment of psoriasis in people living with controlled HIV: inference-based guidance from a multidisciplinary expert panel. Dermatol Ther (Heidelb). 2022;12(5):1073–1089. doi: 10.1007/S13555-022-00722-0
   PubMed Web of Science ®Google Scholar
• Ion A, AM D, Popa LG, et al. Risks of biologic therapy and the importance of multidisciplinary approach for an accurate management of patients with moderate-severe psoriasis and concomitant diseases. Biology. 2022;11(6):808. doi: 10.3390/BIOLOGY11060808
   PubMedGoogle Scholar
• Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020;183(2):373–374. doi: 10.1111/BJD.19158
   PubMed Web of Science ®Google Scholar
• Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021;147(1):60–71. doi: 10.1016/J.JACI.2020.10.007
   PubMed Web of Science ®Google Scholar
• Butrón-Bris B, Daudén E, Rodríguez-Jiménez P. Psoriasis Therapy and Skin Cancer: A Review. Life (Basel). 2021;11(10):1109. doi: 10.3390/LIFE11101109
   PubMed Web of Science ®Google Scholar
• Vaengebjerg S, Skov L, Egeberg A, et al. Incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(4):421–429. doi: 10.1001/JAMADERMATOL.2020.0024
   PubMed Web of Science ®Google Scholar
• Liu R, Wan Q, Zhao R, et al. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis. Cancer Cell Int. 2021;21(1). doi: 10.1186/S12935-021-02325-9
   Web of Science ®Google Scholar
• Fiorentino D, Ho V, Lebwohl MG, et al. Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. J Am Acad Dermatol. 2017;77(5):845–854.e5. doi: 10.1016/J.JAAD.2017.07.013
   PubMed Web of Science ®Google Scholar
• Rusiñol L, Camiña-Conforto G, Puig L. Biologic treatment of psoriasis in oncologic patients. Expert Opin Biol Ther. 2022;22(12):1567–1578. doi: 10.1080/14712598.2022.2152322
   PubMed Web of Science ®Google Scholar
• Jung JM, Kim YJ, Chang SE, et al. Cancer risks in patients with psoriasis administered biologics therapy: a nationwide population-based study. J Cancer Res Clin Oncol. 2023;149(19):17093–17102. doi: 10.1007/S00432-023-05387-6
   PubMed Web of Science ®Google Scholar
• Kridin K, Abdelghaffar M, Mruwat N, et al. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?—Insights from an international population-based study. J Eur Acad Dermatol Venereol. 2024;38(2):315–324. doi: 10.1111/JDV.19520 Published online 2023.
   PubMed Web of Science ®Google Scholar
• González-Parra E, Daudén E, Carrascosa JM, et al. Kidney disease and psoriasis. a new comorbidity? Actas Dermosifiliogr. 2016;107(10):823–829. doi: 10.1016/J.AD.2016.05.009
   PubMedGoogle Scholar
• Egeberg A, Thyssen JP, Burisch J, et al. Incidence and risk of inflammatory bowel disease in patients with psoriasis-A nationwide 20-year cohort study. J Invest Dermatol. 2019;139(2):316–323. doi: 10.1016/J.JID.2018.07.029
   PubMed Web of Science ®Google Scholar
• Alinaghi F, Tekin HG, Burisch J, et al. Global prevalence and bidirectional association between psoriasis and inflammatory bowel disease-a systematic review and meta-analysis. J Crohns Colitis. 2020;14(3):351–360. doi: 10.1093/ECCO-JCC/JJZ152
   PubMed Web of Science ®Google Scholar
• Liang X, Peng Z, Deng Y, et al. The role of T cells and shared genes in psoriasis and inflammatory bowel disease based on single-cell RNA and comprehensive analysis. Immunobiology. 2023;228(6):152754. doi: 10.1016/J.IMBIO.2023.152754
   PubMed Web of Science ®Google Scholar
• Yiu TH, Ko Y, Pudipeddi A, et al. Comparing persistence of new biologics to conventional anti-TNF alphas in adult patients with inflammatory bowel disease: a systematic review and meta-analysis protocol. BMJ Open. 2023;13(10):e073071. doi: 10.1136/BMJOPEN-2023-073071
   PubMed Web of Science ®Google Scholar
• Juillerat P, Grueber MM, Ruetsch R, et al. Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom? Current Res Pharmacol Drug Discov. 2022;3:3. doi: 10.1016/J.CRPHAR.2022.100104
   Google Scholar
• Verstockt B, Salas A, Sands BE, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20(7):433–446. doi: 10.1038/S41575-023-00768-1
   PubMed Web of Science ®Google Scholar
• Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022;399(10342):2200–2211. doi: 10.1016/S0140-6736(22)00688-2
   PubMed Web of Science ®Google Scholar
• Dubinsky M, Ma C, Griffith J, et al. Matching-adjusted indirect comparison between risankizumab and ustekinumab for induction and maintenance treatment of moderately to severely active crohn’s disease. Adv Ther. 2023;40(9):3896–3911. doi: 10.1007/S12325-023-02546-6
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Stange EF. Prioritization in inflammatory bowel disease therapy. Expert Rev Gastroenterol Hepatol. 2023;17(8):753–767. doi: 10.1080/17474124.2023.2240699
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Allegretti JR, Rubin DT, et al. Guselkumab in patients with moderately to severely active uicerative colitis: QUASAR phase 2b induction study. Gastroenterology. Published online Sep 2023;165(6):1443–1457. doi: 10.1053/J.GASTRO.2023.08.038
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, D’Haens GR, Reinisch W, et al. Guselkumab for the treatment of crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162(6):1650–1664.e8. doi: 10.1053/J.GASTRO.2022.01.047
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700. doi: 10.1136/GUTJNL-2011-301668
   PubMed Web of Science ®Google Scholar
• Marin M, Alzueta N, Pío M, et al. Ulcerative colitis induced by ixekizumab: a case report. Eur J Hosp Pharm. 2021;28(1):50–52. doi: 10.1136/ejhpharm-2019-002016
   PubMedGoogle Scholar
• Saito K, Yoza K, Takeda S, et al. Drug-induced entero-colitis due to interleukin-17 inhibitor use; capsule endoscopic findings and pathological characteristics: a case report. World J Gastroenterol. 2023;29(32):4912–4919. doi: 10.3748/wjg.v29.i32.4912
   PubMed Web of Science ®Google Scholar
• Jiang Y, Chen Y, Yu Q, et al. Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities. BioDrugs. 2023;37(1):35–55. doi: 10.1007/S40259-022-00569-Z
   PubMed Web of Science ®Google Scholar
• Hölsken S, Krefting F, Schedlowski M, et al. Common fundamentals of psoriasis and depression. Acta Derm Venereol. 2021;101(11):adv00609. doi: 10.2340/ACTADV.V101.565
   PubMedGoogle Scholar
• Wang X, Li Y, Wu L, et al. Dysregulation of the gut-brain-skin axis and key overlapping inflammatory and immune mechanisms of psoriasis and depression. Biomed Pharmacother. 2021;137:137. doi: 10.1016/J.BIOPHA.2020.111065
   Web of Science ®Google Scholar
• Strober B, Gooderham M, de Jong EMGJ, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in psoriasis longitudinal assessment and registry (PSOLAR). J Am Acad Dermatol. 2018;78(1):70–80. doi: 10.1016/J.JAAD.2017.08.051
   PubMed Web of Science ®Google Scholar
• Timis TL, Beni L, Mocan T, et al. Biologic therapies decrease disease severity and improve depression and anxiety symptoms in psoriasis patients. Life (Basel). 2023;13(5):1219. doi: 10.3390/LIFE13051219
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi: 10.1056/NEJMOA1503824
   PubMed Web of Science ®Google Scholar
• Andersch-Björkman Y, Micu E, Seifert O, et al. Effects of brodalumab on psoriasis and depressive symptoms in patients with insufficient response to TNF-α inhibitors. J Dermatol. 2023;50(11):1401–1414. doi: 10.1111/1346-8138.16917 Published online 2023.
   PubMed Web of Science ®Google Scholar
• Ohata C, Kanai Y, Murotani K, et al. Effectiveness of long-term treatment with brodalumab on anxiety or depressive symptoms in japanese patients with psoriasis: the ProLOGUE Study. Dermatol Ther (Heidelb). 2023;13(4):1039–1052. doi: 10.1007/S13555-023-00909-Z
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Leonardi C, Armstrong A, et al. Three-year U.S. pharmacovigilance report of brodalumab. Dermatol Ther. 2021;34(6). doi: 10.1111/DTH.15105
   PubMed Web of Science ®Google Scholar
• Amanat M, Salehi M, Rezaei N. Neurological and psychiatric disorders in psoriasis. Rev Neurosci. 2018;29(7):805–813. doi: 10.1515/REVNEURO-2017-0108
   PubMed Web of Science ®Google Scholar
• Mahil SK, Andrews TC, Brierley C, et al. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. J DermatolTreat. 2013;24(1):38–49. doi: 10.3109/09546634.2012.660520
   Google Scholar
• Kaltsonoudis E, Voulgari PV, Konitsiotis S, et al. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13(1):54–58. doi: 10.1016/J.AUTREV.2013.09.002
   PubMed Web of Science ®Google Scholar
• Gharib MH, MA A, Garcia Canibano B, et al. Demyelinating neurological adverse events following the use of Anti-TNF- α agents: A double-edged sword. Case Rep Neurol Med. 2022;2022:1–5. doi: 10.1155/2022/3784938
   Web of Science ®Google Scholar
• Boggs JME, Barnes L. Demyelination during anti-tumour necrosis factor therapy for psoriasis. Clin Exp Dermatol. 2018;43(5):577–578. doi: 10.1111/CED.13412
   PubMed Web of Science ®Google Scholar
• Zhu TH, Nakamura M, Abrouk M, et al. Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: a review. J DermatolTreat. 2016;27(5):406–413. doi: 10.3109/09546634.2015.1136385
   Google Scholar
• Qu Y, Li D, Liu W, et al. Molecular consideration relevant to the mechanism of the comorbidity between psoriasis and systemic lupus erythematosus (Review). Exp Ther Med. 2023;26(4). doi: 10.3892/ETM.2023.12181
   PubMed Web of Science ®Google Scholar
• Zalla MJ, Muller SA. The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders. Acta Dermato-Venereologica, Supplement. 1996;76(195):1–15. doi: 10.2340/00015555195115
   Google Scholar
• A H, AG Y. Anti-tumor necrosis factor-α induced systemic lupus erythematosus(). Open Rheumatol J. 2012;6(1):315–319. doi: 10.2174/1874312901206010315
   PubMedGoogle Scholar
• Haroon MM, Hegazy GA, Hassanien MA, et al. Significance of interleukin 23 in systemic lupus patients: relation to disease activity and damage indices. Biologics. 2023;17:1–9. doi: 10.2147/BTT.S389021
   PubMedGoogle Scholar
• Petrić M, Radić M. Is Th17-targeted therapy effective in Systemic lupus erythematosus? Curr Issues Mol Biol. 2023;45(5):4331–4343. doi: 10.3390/CIMB45050275
   PubMed Web of Science ®Google Scholar
• Barber C, Song EJ. New-onset systemic lupus erythematous in a patient receiving risankizumab for psoriasis. JAAD Case Rep. 2022;25:104–106. doi: 10.1016/j.jdcr.2022.05.039
   PubMedGoogle Scholar
• Dainichi T, Kabashima K. Interaction of psoriasis and bullous diseases. Front Med. 2018;5(AUG). doi: 10.3389/FMED.2018.00222
   Google Scholar
• Maronese CA, Cassano N, Genovese G, et al. The intriguing links between psoriasis and bullous pemphigoid. J Clin Med. 2022;12(1):328. doi: 10.3390/JCM12010328
   PubMed Web of Science ®Google Scholar
• Dainichi T, Koga H, Tsuji T, et al. From anti-p200 pemphigoid to anti-laminin gamma1 pemphigoid. J Dermatol. 2010;37(3):231–238. doi: 10.1111/J.1346-8138.2009.00793.X
   PubMed Web of Science ®Google Scholar
• Arregui Murua MA, Soloeta R, González R, et al. Bullous pemphigoid related to PUVA therapy: two further cases. Actas Dermosifiliogr. 2006;97(7):444–447. doi: 10.1016/S0001-7310(06)73437-8
   PubMedGoogle Scholar
• Wang R, Wang A, Wang M. Two cases with bullous pemphigoid relapsed after using interleukin-17A inhibitors for psoriasis: a paradoxical reaction. J Dermatol. 2023;50(7):956–959. doi: 10.1111/1346-8138.16765
   PubMed Web of Science ®Google Scholar
• Kong L, Huang D, Lu J, et al. Development of bullous pemphigoid during treatment of psoriasis with ustekinumab: a case report and literature review. Front Med. 2023;10:10. doi: 10.3389/FMED.2023.1171802
   Web of Science ®Google Scholar
• Zhang J, Wang SH, Zuo YG. Paradoxical phenomena of bullous pemphigoid induced and treated by identical biologics. Front Immunol. 2023;13:13. doi: 10.3389/FIMMU.2022.1050373
   Web of Science ®Google Scholar
• McInnes IB, Sawyer LM, Markus K, et al. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open. 2022;8(1):e002074. doi: 10.1136/RMDOPEN-2021-002074
   PubMed Web of Science ®Google Scholar
• Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–2284. doi: 10.1016/S0140-6736(18)30830-4
   PubMed Web of Science ®Google Scholar
• Remicade | European Medicines Agency. [cited 2023 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/remicade
   Google Scholar
• Humira | European Medicines Agency. [cited 2023 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/humira
   Google Scholar
• Enbrel | European Medicines Agency. [cited 2023 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel
   Google Scholar
• Cimzia | European Medicines Agency. [cited 2023 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia
   Google Scholar
• Stelara | European Medicines Agency. [cited 2023 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/stelara
   Google Scholar
• Cosentyx | European Medicines Agency. [cited 2023 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx
   Google Scholar
• Taltz | European Medicines Agency. [cited 2023 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/taltz
   Google Scholar
• Bimzelx | European Medicines Agency. [cited 2023 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx#authorisation-details-section
   Google Scholar
• Tremfya | European Medicines Agency. [cited 2023 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya
   Google Scholar
• Skyrizi | European Medicines Agency. [cited 2023 Oct 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi
   Google Scholar
• Ruyssen-Witrand A, Perry R, Watkins C, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020;6(1):e001117. doi: 10.1136/RMDOPEN-2019-001117
   PubMed Web of Science ®Google Scholar
• Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford). 2021;60(5):2109–2121. doi: 10.1093/RHEUMATOLOGY/KEAB119
   PubMed Web of Science ®Google Scholar
• Mourad A, Gniadecki R. Treatment of dactylitis and enthesitis in psoriatic arthritis with biologic agents: a systematic review and meta analysis. J Rheumatol. 2020;47(1):59–65. doi: 10.3899/JRHEUM.180797
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 maximise trial. Ann Rheum Dis. 2021;80(5):582–590. doi: 10.1136/ANNRHEUMDIS-2020-218808
   PubMed Web of Science ®Google Scholar
• Deodhar A, Gladman D, Bolce R, et al. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2. Ther Adv Musculoskelet Dis. 2023;15:15. doi: 10.1177/1759720X231189005
   Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Poddubnyy D, et al. Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled DISCOVER-2 study. Rheumatol Ther. Published online Oct 11, 2023;10(6):1637–1653. doi: 10.1007/S40744-023-00592-8
   PubMed Web of Science ®Google Scholar
• Sundanum S, Orr C, Veale D. Targeted therapies in Psoriatic Arthritis—an update. Int J Mol Sci. 2023;24(7):6384. doi: 10.3390/IJMS24076384
   PubMed Web of Science ®Google Scholar
• Deodhar A, Machado PM, Mørup M, et al. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford). Published online Nov 8, 2023. doi: 10.1093/RHEUMATOLOGY/KEAD598
   Web of Science ®Google Scholar
• Jiang C, Du Y, Liu X, et al. Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody targeting IL-17A, in healthy subjects and patients with moderate to severe plaque psoriasis (PsO). Br J Dermatol. Cites Sep 5, 2023;190(1):28–36. doi: 10.1093/BJD/LJAD315
   PubMed Web of Science ®Google Scholar
• Lee HJ, Kim M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci. 2023;24(17):13313. doi: 10.3390/IJMS241713313
   PubMed Web of Science ®Google Scholar
• Thakur V, Mahajan R. Novel therapeutic target(s) for psoriatic disease. Front Med (Lausanne). 2022 Feb 21;9:712313. doi: 10.3389/FMED.2022.712313. PMID: 35265634; PMCID: PMC8898896.
   PubMed Web of Science ®Google Scholar